HPE
45
7
FLS
65
2
CL
56
-2
SHW
55
-3
JNJ
54
-6
SBUX
40
-3
EXPE
81
-2
ALLE
39
-5
EXR
22
-17
NRG
60
3
FIS
53
-2
CF
48
3
KSS
59
-5
DUK
55
-2
AAP
36
-5
ORLY
50
2
GILD
49
-2
VRTX
53
-3
PRGO
29
-2
HAS
61
-3
HPE
45
7
FLS
65
2
CL
56
-2
SHW
55
-3
JNJ
54
-6
SBUX
40
-3
EXPE
81
-2
ALLE
39
-5
EXR
22
-17
NRG
60
3
FIS
53
-2
CF
48
3
KSS
59
-5
DUK
55
-2
AAP
36
-5
ORLY
50
2
GILD
49
-2
VRTX
53
-3
PRGO
29
-2
HAS
61
-3
Financhill
Back

Entrada Therapeutics, Inc. 10K Form

Buy
71

TRDA
Entrada Therapeutics, Inc.

Last Price:
$10.18
Seasonality Move:
-3.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TRDA News And Ratings

See the #1 stock for the next 7 days that we like better than TRDA

TRDA Financial Statistics

Sales & Book Value

Annual Sales: $210.8M
Cash Flow: $-28.1M
Price / Cash Flow: 0
Annual Sales: $8.91
Price / Book: 1.14

Profitability

EPS (TTM): -2.50320
Net Income (TTM): $-103.5M
Gross Margin: $207M
Return on Equity: -26.01%
Return on Assets: -21.3%

Entrada Therapeutics, Inc. Earnings Forecast

Key Entrada Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 6 years for TRDA is 98.21%.
  • The Selling, General & Administrative Expenses for TRDA have been equal to 18.25% of Gross Profit Margin.
  • The Research & Development expenses have been 57.66% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of TRDA is 31.13% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Entrada Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: TRDA
Website: entradatx.com

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 14.08
Quick Ratio: 13.66

Price-to-Earnings

Trailing P/E Ratio: 6.04
Forward P/E Ratio: 0

TRDA Technical Analysis vs Fundamental Analysis

Buy
71
Entrada Therapeutics, Inc. (TRDA) is a Buy

Is Entrada Therapeutics, Inc. a Buy or a Sell?